References of "Bensen, W"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEfficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial.
Reginster, Jean-Yves ULg; Badurski, J; Bellamy, N et al

in Annals of the Rheumatic Diseases (2013), 72(2), 179-86

BACKGROUND: Strontium ranelate is currently used for osteoporosis. The international, double-blind, randomised, placebo-controlled Strontium ranelate Efficacy in Knee OsteoarthrItis triAl evaluated its ... [more ▼]

BACKGROUND: Strontium ranelate is currently used for osteoporosis. The international, double-blind, randomised, placebo-controlled Strontium ranelate Efficacy in Knee OsteoarthrItis triAl evaluated its effect on radiological progression of knee osteoarthritis. METHODS: Patients with knee osteoarthritis (Kellgren and Lawrence grade 2 or 3, and joint space width (JSW) 2.5-5 mm) were randomly allocated to strontium ranelate 1 g/day (n=558), 2 g/day (n=566) or placebo (n=559). The primary endpoint was radiographical change in JSW (medial tibiofemoral compartment) over 3 years versus placebo. Secondary endpoints included radiological progression, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, and knee pain. The trial is registered (ISRCTN41323372). RESULTS: The intention-to-treat population included 1371 patients. Treatment with strontium ranelate was associated with smaller degradations in JSW than placebo (1 g/day: -0.23 (SD 0.56) mm; 2 g/day: -0.27 (SD 0.63) mm; placebo: -0.37 (SD 0.59) mm); treatment-placebo differences were 0.14 (SE 0.04), 95% CI 0.05 to 0.23, p<0.001 for 1 g/day and 0.10 (SE 0.04), 95% CI 0.02 to 0.19, p=0.018 for 2 g/day. Fewer radiological progressors were observed with strontium ranelate (p<0.001 and p=0.012 for 1 and 2 g/day). There were greater reductions in total WOMAC score (p=0.045), pain subscore (p=0.028), physical function subscore (p=0.099) and knee pain (p=0.065) with strontium ranelate 2 g/day. Strontium ranelate was well tolerated. CONCLUSIONS: Treatment with strontium ranelate 1 and 2 g/day is associated with a significant effect on structure in patients with knee osteoarthritis, and a beneficial effect on symptoms for strontium ranelate 2 g/day. [less ▲]

Detailed reference viewed: 17 (8 ULg)
Full Text
Peer Reviewed
See detailStructure modifying effects of strontium ranelate in knee osteoarthritis
Reginster, Jean-Yves ULg; Chapurlat, R; Christiaensen, C et al

in Osteoporosis International (2012, March), 23(S2), 58-59

Detailed reference viewed: 117 (5 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the number of radiological or radioclinical progressors in patients with primary knee osteoarthritis
Reginster, Jean-Yves ULg; Chapurlat, R; Christiansen, C et al

in Osteoporosis International (2012, March), 23(S2), 366-367

Detailed reference viewed: 42 (2 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate in knee osteoarthritis trial (SEKOIA) : a structural and symptomatic efficacy
Reginster, Jean-Yves ULg; Chapurlat, R; Christiansen, C et al

in Arthritis and Rheumatism (2012), 64(S10), 681

Detailed reference viewed: 42 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of strontium ranelate in the treatment of knee osteoarthritis : a randomized, double-blind, placebo-controlled international trial
Cooper, C; Chapurlat, R; Christiansen, C et al

in Annals of the Rheumatic Diseases (2012), 71(3), 693

Detailed reference viewed: 29 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of strontium ranelate in the treatment of knee ostoarthritis : a randomized, double-blind, placebo-controlled international trial
Reginster, Jean-Yves ULg; Chapurlat, R.; Christiansen, C. et al

in Osteoporosis International (2011), 22(S5), 742-743

Detailed reference viewed: 48 (1 ULg)
Full Text
Peer Reviewed
See detailThe effect of risedronate on hip fracture risk in elderly women with osteoporosis
Bensen, W; Eastell, R; Reginster, Jean-Yves ULg et al

in Journal of Rheumatology (2001), 28(S63), 24

Detailed reference viewed: 1 (1 ULg)
Full Text
Peer Reviewed
See detailRisedronate reduces hip fracture risk in elderly women with osteoporosis
McClung, M; Eastell, R; Bensen, W et al

in Osteoporosis International (2000), 11(S2), 207

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailRisedronate significantly reduces hip fracture risk in elderly women with osteoporosis
Bensen, W; Piette, F; Ettinger, M et al

in Journal of Bone and Mineral Research (2000), 15(S1), 226

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailRapid and sustained effects of risedronate in reducting hip fracture risk in elderly women with osteoporis
Seeman, E; McClung, M; Zippel, H et al

in Journal of Bone and Mineral Research (2000), 15(S1), 149

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailRisedronate reduces hip fracture risk in elderly women with osteoporosis with a rapid and sustained effect
Silverman, S; Geusens, P; Bensen, W et al

in Arthritis and Rheumatism (2000), 43(S1), 781

Detailed reference viewed: 8 (1 ULg)